Novartis Historical Income Statement

NVS Stock

USD 104.87 1.06 1.02%

Historical analysis of Novartis income statement accounts such as Selling And Marketing Expenses of 12.8 B can show how well Novartis AG ADR performed in making a profits. Evaluating Novartis income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Novartis's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Novartis AG ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Novartis AG ADR is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

About Novartis Income Statement Analysis

Novartis AG ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Novartis shareholders. The income statement also shows Novartis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Novartis Income Statement Chart

At this time, Novartis' Discontinued Operations is comparatively stable compared to the past year. Net Income From Continuing Ops is likely to gain to about 10.8 B in 2024, whereas Selling And Marketing Expenses is likely to drop slightly above 12.8 B in 2024.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit Total Operating Expenses

Total Revenue

Total revenue comprises all receipts Novartis AG ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Novartis AG ADR minus its cost of goods sold. It is profit before Novartis operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Novartis' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

	2021	2022	2023	2024 (projected)
Gross Profit	37.0B	36.3B	34.2B	32.3B
Total Revenue	52.9B	51.8B	46.7B	46.2B

Gross Profit Total Revenue

Novartis income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest	Discontinued Operations	Net Income From Continuing Ops	Tax Provision	Interest Income	Extraordinary Items	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.09	0.25	0.41	0.24	0.36	0.16	0.29	-0.56	0.34	0.09	-0.01	0.28	0.15	-0.27	0.36	-0.28	-0.29	0.47	0.13	0.06	0.15	0.33	0.23	0.55
Interest Expense	0.09		0.49	0.8	0.78	0.81	0.79	0.29	0.59	0.9	0.87	0.63	0.85	0.35	-0.02	0.32	0.16	0.15	0.14	0.08	0.34	0.09	-0.44	-0.16	0.21
Selling General Administrative	0.25	0.49		0.23	0.04	0.17	0.03	0.28	0.2	0.32	0.34	-0.2	0.2	0.36	-0.22	0.29	-0.04	-0.53	0.41	0.32	0.7	0.25	-0.54	-0.02	0.56
Selling And Marketing Expenses	0.41	0.8	0.23		0.89	0.93	0.86	0.29	0.34	0.91	0.8	0.7	0.93	0.26	-0.02	0.26	-0.02	0.32	0.03	0.02	0.09	0.01	-0.09	0.11	0.26
Total Revenue	0.24	0.78	0.04	0.89		0.98	0.99	0.35	0.43	0.83	0.8	0.93	0.98	0.37	-0.02	0.28	0.23	0.52	-0.07	0.11	-0.01	0.09	0.02	-0.14	-0.11
Gross Profit	0.36	0.81	0.17	0.93	0.98		0.95	0.42	0.35	0.88	0.8	0.83	0.98	0.4	-0.1	0.32	0.23	0.41	0.01	0.14	0.1	0.14	0.02	-0.11	0.01
Other Operating Expenses	0.16	0.79	0.03	0.86	0.99	0.95		0.27	0.49	0.82	0.81	0.95	0.97	0.3	0.06	0.23	0.19	0.54	-0.08	0.04	-0.05	0.02	-0.04	-0.11	-0.12
Operating Income	0.29	0.29	0.28	0.29	0.35	0.42	0.27		0.0	0.32	0.3	0.2	0.3	0.94	-0.9	0.76	0.51	-0.19	0.15	0.89	0.57	0.95	0.01	-0.47	-0.11
Ebit	-0.56	0.59	0.2	0.34	0.43	0.35	0.49	0.0		0.35	0.71	0.53	0.43	0.24	0.27	0.04	0.06	0.32	-0.37	0.11	0.11	-0.06	-0.58	-0.05	-0.13
Research Development	0.34	0.9	0.32	0.91	0.83	0.88	0.82	0.32	0.35		0.82	0.65	0.89	0.28	-0.09	0.38	-0.01	0.14	0.2	0.01	0.16	0.08	-0.23	0.07	0.32
Ebitda	0.09	0.87	0.34	0.8	0.8	0.8	0.81	0.3	0.71	0.82		0.71	0.82	0.45	0.08	0.41	0.04	0.28	-0.11	0.23	0.09	0.1	-0.3	-0.03	0.22
Cost Of Revenue	-0.01	0.63	-0.2	0.7	0.93	0.83	0.95	0.2	0.53	0.65	0.71		0.86	0.26	0.13	0.19	0.21	0.66	-0.2	0.03	-0.2	-0.01	0.01	-0.18	-0.32
Total Operating Expenses	0.28	0.85	0.2	0.93	0.98	0.98	0.97	0.3	0.43	0.89	0.82	0.86		0.31	0.01	0.25	0.17	0.42	0.01	0.05	0.06	0.04	-0.08	-0.05	0.03
Income Before Tax	0.15	0.35	0.36	0.26	0.37	0.4	0.3	0.94	0.24	0.28	0.45	0.26	0.31		-0.75	0.76	0.48	-0.14	0.01	0.95	0.54	0.9	-0.1	-0.48	-0.1
Total Other Income Expense Net	-0.27	-0.02	-0.22	-0.02	-0.02	-0.1	0.06	-0.9	0.27	-0.09	0.08	0.13	0.01	-0.75		-0.65	-0.42	0.4	-0.3	-0.77	-0.63	-0.94	0.0	0.41	0.08
Net Income	0.36	0.32	0.29	0.26	0.28	0.32	0.23	0.76	0.04	0.38	0.41	0.19	0.25	0.76	-0.65		0.1	-0.23	0.49	0.72	0.34	0.75	0.0	-0.22	0.16
Income Tax Expense	-0.28	0.16	-0.04	-0.02	0.23	0.23	0.19	0.51	0.06	-0.01	0.04	0.21	0.17	0.48	-0.42	0.1		0.36	-0.21	0.4	0.32	0.46	0.24	-0.79	-0.69
Minority Interest	-0.29	0.15	-0.53	0.32	0.52	0.41	0.54	-0.19	0.32	0.14	0.28	0.66	0.42	-0.14	0.4	-0.23	0.36		-0.42	-0.27	-0.48	-0.34	0.43	-0.22	-0.6
Discontinued Operations	0.47	0.14	0.41	0.03	-0.07	0.01	-0.08	0.15	-0.37	0.2	-0.11	-0.2	0.01	0.01	-0.3	0.49	-0.21	-0.42		-0.02	0.37	0.16	-0.03	0.06	0.31
Net Income From Continuing Ops	0.13	0.08	0.32	0.02	0.11	0.14	0.04	0.89	0.11	0.01	0.23	0.03	0.05	0.95	-0.77	0.72	0.4	-0.27	-0.02		0.5	0.92	-0.06	-0.43	-0.07
Tax Provision	0.06	0.34	0.7	0.09	-0.01	0.1	-0.05	0.57	0.11	0.16	0.09	-0.2	0.06	0.54	-0.63	0.34	0.32	-0.48	0.37	0.5		0.57	-0.5	-0.38	0.09
Interest Income	0.15	0.09	0.25	0.01	0.09	0.14	0.02	0.95	-0.06	0.08	0.1	-0.01	0.04	0.9	-0.94	0.75	0.46	-0.34	0.16	0.92	0.57		-0.05	-0.47	-0.12
Extraordinary Items	0.33	-0.44	-0.54	-0.09	0.02	0.02	-0.04	0.01	-0.58	-0.23	-0.3	0.01	-0.08	-0.1	0.0	0.0	0.24	0.43	-0.03	-0.06	-0.5	-0.05		-0.02	-0.33
Net Interest Income	0.23	-0.16	-0.02	0.11	-0.14	-0.11	-0.11	-0.47	-0.05	0.07	-0.03	-0.18	-0.05	-0.48	0.41	-0.22	-0.79	-0.22	0.06	-0.43	-0.38	-0.47	-0.02		0.55
Reconciled Depreciation	0.55	0.21	0.56	0.26	-0.11	0.01	-0.12	-0.11	-0.13	0.32	0.22	-0.32	0.03	-0.1	0.08	0.16	-0.69	-0.6	0.31	-0.07	0.09	-0.12	-0.33	0.55

Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	171.9K	5.1B	5.4B	6.7B	8.3B	8.7B
Interest Expense	850M	869M	811M	837M	855M	550.6M
Selling General Administrative	14.4B	14.2B	14.8B	14.3B	14.3B	15.0B
Total Revenue	48.7B	49.9B	52.9B	51.8B	46.7B	46.2B
Gross Profit	34.3B	34.8B	37.0B	36.3B	34.2B	32.3B
Other Operating Expenses	39.6B	39.7B	41.2B	42.6B	36.9B	36.9B
Operating Income	9.1B	10.2B	26.9B	9.2B	9.8B	9.9B
Ebit	15.6B	10.1B	11.7B	8.0B	10.0B	10.9B
Research Development	9.4B	9.0B	9.5B	10.0B	11.4B	7.8B
Ebitda	15.6B	15.2B	17.1B	14.7B	18.3B	14.0B
Cost Of Revenue	14.4B	15.1B	15.9B	15.5B	12.5B	13.9B
Total Operating Expenses	25.2B	24.6B	25.3B	27.1B	24.4B	23.0B
Income Before Tax	8.9B	9.9B	26.1B	8.4B	9.1B	10.2B
Total Other Income Expense Net	(146M)	(274M)	(16.2B)	425M	(646M)	(613.7M)
Net Income	7.1B	8.1B	24.0B	7.0B	14.9B	9.7B
Income Tax Expense	1.8B	1.8B	2.1B	1.4B	551M	523.5M
Net Income Applicable To Common Shares	11.7B	8.1B	24.0B	7.0B	8.0B	9.8B
Minority Interest	77M	68M	3M	2M	(4M)	(3.8M)
Net Income From Continuing Ops	7.1B	8.1B	24.0B	7.0B	8.2B	10.8B
Tax Provision	1.8B	1.8B	2.1B	1.4B	1.4B	1.7B
Interest Income	36M	91M	14.6B	379M	627M	595.7M
Net Interest Income	(645M)	(947M)	(891M)	(633M)	(492M)	(516.6M)
Reconciled Depreciation	5.8B	6.5B	6.1B	7.2B	9.0B	7.5B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novartis Historical Income Statement

About Novartis Income Statement Analysis

Novartis Income Statement Chart

Total Revenue

Gross Profit

Total Operating Expenses

Novartis income statement Correlations

Novartis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novartis income statement Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Novartis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 0.99	Total Revenue
Gross Profit	+ 0.98	Total Revenue
Total Operating Expenses	+ 0.98	Total Revenue
Total Operating Expenses	+ 0.98	Gross Profit
Total Operating Expenses	+ 0.97	Other Operating Expenses
Other Operating Expenses	+ 0.95	Gross Profit

Interest Income	- 0.94	Total Other Income Expense Net
Total Other Income Expense Net	- 0.9	Operating Income
Net Interest Income	- 0.79	Income Tax Expense
Net Income From Continuing Ops	- 0.77	Total Other Income Expense Net
Total Other Income Expense Net	- 0.75	Income Before Tax
Reconciled Depreciation	- 0.69	Income Tax Expense